NASDAQ · CRBU
Healthcare · Biotechnology
$1.22
Up+$0.00 (+0.00%)
Updated Oct 3, 2026, 9:54 PM
SID Score
2.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · CRBU
1M range · 0 trading sessions · Daily adjusted prices
CRBU does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning CRBU.
Company
Market Activity
Research & News
CRBU research
Company profile and research snapshot.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 14, 2026 | B of A Securities | Buy | — |
| May 11, 2026 | HC Wainwright & Co. | Buy | — |
| Apr 7, 2026 | HC Wainwright & Co. | Buy | — |
| Mar 9, 2026 | Evercore ISI Group | Outperform | — |
| Feb 2, 2026 | Clear Street | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 14, 2026
The heavy selling pressure might have exhausted for Caribou Biosciences (CRBU) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Benzinga · Aug 14, 2026
B of A Securities analyst Alec Stranahan maintains Caribou Biosciences (NASDAQ:CRBU) with a Buy and lowers the price target from $6 to $5.
Benzinga · Aug 13, 2026
Caribou Biosciences (NASDAQ:CRBU) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.32) by 25 percent. This is a 31.43 percent increase over losses of $(0.35) per share from
Yahoo · Jun 29, 2026
BERKELEY, Calif., June 29, 2026 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced Rachel Haurwitz, PhD, Caribou’s president and chief executive officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 10:00 am ET. For more information and a link to the webcast, visit the Events page on Caribou’s website. Webcasts will be
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRBU.
